High-Performance Polymers · EURONEXT PARIS: AKE
Arkema: one of the broadest public portfolios of high-performance materials for polymer additive manufacturing.
Rilsan PA11, Orgasol PA12, Kepstan PEKK, Pebax elastomers and N3xtDimension UV-curable systems give Arkema exposure across powder-bed fusion, extrusion and vat photopolymerization.
As of: 18 July 2026 · Profile: Qualified polymer feedstock and formulation · Recommendation: None
Investor read
Arkema reported Q1 2026 EBITDA of €283 million and a 13.0% EBITDA margin, while batteries, sports, 3D printing and healthcare together grew roughly 15% year over year.
The equity thesis is driven by specialty-material demand, pricing, FX, major project ramp-ups, High Performance Polymers, adhesives, working capital and energy or feedstock costs. Additive manufacturing is strategically attractive but financially undisclosed.
Arkema’s AM advantage is breadth. It can supply rigid, ductile, flexible, chemical-resistant, high-temperature and UV-curable chemistries across several printing platforms rather than relying on one process or material family.
High-signal metrics
| Metric | Period | Investor interpretation |
|---|---|---|
| €283M EBITDA | Q1 2026 | Down from €329 million a year earlier but 14% above Q4 2025. |
| 13.0% EBITDA margin | Q1 2026 | Versus 13.8% in Q1 2025. |
| ~15% growth | Q1 2026 | Combined key attractive markets: batteries, sports, 3D printing and healthcare. |
| Stable group volumes | Q1 2026 | Growth across all Specialty Materials segments offset soft Europe and U.S. demand. |
| €95M recurring cash outflow | Q1 2026 | Seasonal, but improved versus the prior year. |
| ~€50M incremental EBITDA | 2026 project target | Expected contribution from major project ramp-ups versus 2025. |
| ~€600M capex | FY2026 plan | Maintains investment while controlling cash deployment. |
| Slight EBITDA growth | FY2026 outlook | Targeted at constant currencies. |
AM materials portfolio
| Material family | Process and capability | Bottleneck role |
|---|---|---|
| Rilsan PA11 | SLS, MJF and SAF powder-bed fusion | Bio-based, ductile and impact-resistant material for end-use parts. |
| Orgasol PA12 | Fine polyamide powders | Established processing behavior and broad application compatibility. |
| Kepstan PEKK | PBF and extrusion-grade high-temperature polymer | Metal replacement, chemical resistance and flame performance. |
| Pebax elastomers | Flexible and energy-return applications | Supports sports, footwear and flexible functional parts. |
| N3xtDimension systems | SLA, DLP and material-jetting resins | Tunes toughness, transparency, heat resistance and durability. |
| Sartomer monomers and oligomers | Custom radiation-curable formulation building blocks | Allows resin formulators to engineer application-specific properties. |
Why Arkema controls an AM bottleneck
- Portfolio breadth: powders, pellets, filaments and liquid-resin building blocks span multiple AM processes.
- High-performance chemistry: PA11 and PEKK address demanding mechanical, chemical and thermal requirements.
- Application-specific formulation: Sartomer and N3xtDimension allow tailored photopolymer performance.
- Bio-based differentiation: Rilsan PA11 originates from renewable castor oil.
- Production-part relevance: Arkema positions PA11 for automotive, aerospace, medical and industrial end-use parts.
- Qualification support: material consistency and printer partnerships lower adoption friction.
- Cross-market scale: polymers are supported by a much larger specialty-material manufacturing base.
Financial materiality
Emerging: AM can influence a business line or the strategic thesis, but is not yet dominant.
Addithive scorecard
| Dimension | Assessment | Rationale |
|---|---|---|
| Pure-play | 1 / 5 | AM is a small capability inside a diversified company. |
| Bottleneck ownership | 4 / 5 | Qualified or serial capability with meaningful switching costs, while viable alternatives remain. |
| Evidence maturity | Qualified | Qualified workflows or customer adoption are visible, but broad serial scale remains limited. |
| Financial materiality | Emerging | AM can influence a business line or the strategic thesis, but is not yet dominant. |
| Substitutability | Medium | Alternatives exist, but replacement requires workflow changes, requalification or integration effort. |
| Evidence confidence | High for cited operational evidence; lower for AM economics | Product, qualification and production claims are source-backed; AM-specific revenue and margin disclosure is often limited. |
Catalysts and thesis breakers
Catalysts
- 3D printing remaining a superior-growth specialty market.
- High Performance Polymers improving in the second half.
- PA11 adoption expanding in serial automotive and medical applications.
- PEKK gaining metal-replacement use cases.
- Printer partnerships accelerating qualification.
- Major projects delivering the targeted €50 million EBITDA uplift.
Thesis breakers
- Raw-material and energy inflation outrunning price increases.
- High Performance Polymers remaining weak.
- PA12 commoditization compressing margins.
- Closed printer ecosystems limiting open-material adoption.
- AM material qualification cycles delaying volume.
- 3D printing growth failing to become financially material.
What to monitor
- First-half 2026 results on 30 July 2026.
- High Performance Polymers volume and pricing.
- Growth in 3D printing and adjacent attractive markets.
- Major-project EBITDA contribution.
- PA11, PA12, PEKK and resin qualification announcements.
- Any AM-specific revenue or volume disclosure.
Evidence gaps
- AM revenue, volume, margin and customer concentration are not disclosed.
- Material mix by printing technology is unavailable.
- Printer-partner economics and qualification timing are not quantified.
- Current consensus, ownership, liquidity and positioning were not sourced.
Source ledger
- Arkema Q1 2026 results — EBITDA, margins, market growth and outlook.
- Arkema 3D printing portfolio — material families and application properties.
- Arkema powder-bed fusion materials — PA11, PA12 and PEKK positioning.
- Rilsan PA11 product page — renewable origin and performance characteristics.
- Arkema Formnext portfolio — current product lineup across AM technologies.
Research conclusion
Arkema owns a meaningful AM materials bottleneck, but investors are buying a diversified specialty-materials company.
The portfolio’s breadth across flexible, bio-based, high-temperature and UV-curable polymers is strategically differentiated. Shareholder returns still depend on pricing, project ramp-ups, specialty demand, FX and cash conversion rather than additive manufacturing alone.
Research use only. This page is not investment advice.
Return to the Public Additive Manufacturing Companies Directory →